Your browser doesn't support javascript.
loading
Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy.
Othman, Jad; Tiong, Ing S; O'Nions, Jenny; Dennis, Mike; Mokretar, Katya; Ivey, Adam; Austin, Michael; Latif, Anne-Louise; Amer, Mariam; Chan, Wei Yee; Crawley, Charles; Crolla, Francesca; Cross, Joe; Dang, Ray; Elliot, Johnathon; Fong, Chun Y; Galli, Sofia; Gallipoli, Paolo; Hogan, Francesca; Kalkur, Pallavi; Khan, Anjum; Krishnamurthy, Pramila; Laurie, John; Loo, Sun; Marshall, Scott; Mehta, Priyanka; Murthy, Vidhya; Nagumantry, Sateesh; Pillai, Srinivas; Potter, Nicola; Sellar, Rob; Taylor, Tom; Zhao, Rui; Russell, Nigel H; Wei, Andrew H; Dillon, Richard.
Afiliación
  • Othman J; Department of Medical and Molecular Genetics, King's College London, London, United Kingdom.
  • Tiong IS; Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
  • O'Nions J; Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
  • Dennis M; Peter MacCallum Cancer Centre, Royal Melbourne Hospital and Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.
  • Mokretar K; Alfred Hospital and Monash University, Melbourne, Australia.
  • Ivey A; Austin Health and Olivia Newton John Cancer Research Institute, Melbourne, Australia.
  • Austin M; Department of Haematology, University College London Hospital NHS Foundation Trust, London, United Kingdom.
  • Latif AL; The Christie NHS Foundation Trust, Manchester, United Kingdom.
  • Amer M; Cancer Genetics, Synnovis, London, United Kingdom.
  • Chan WY; Alfred Hospital and Monash University, Melbourne, Australia.
  • Crawley C; Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
  • Crolla F; Department of Haematology, Queen Elizabeth University Hospital, Glasgow, United Kingdom.
  • Cross J; Haematology, University Hospital Southampton, Southampton, United Kingdom.
  • Dang R; Department of Haematology, University College London Hospital NHS Foundation Trust, London, United Kingdom.
  • Elliot J; Department of Haematology, Addenbrooke's Hospital, Cambridge, United Kingdom.
  • Fong CY; Haematology, Musgrove Park Hospital, Taunton, United Kingdom.
  • Galli S; Haematology Department, University Hospital Bristol, Bristol, United Kingdom.
  • Gallipoli P; James Cook University Hospital, Middlesbrough, United Kingdom.
  • Hogan F; The Christie NHS Foundation Trust, Manchester, United Kingdom.
  • Kalkur P; Austin Health and Olivia Newton John Cancer Research Institute, Melbourne, Australia.
  • Khan A; Frimley Park Hospital, London, United Kingdom.
  • Krishnamurthy P; Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
  • Laurie J; University Hospital of Wales, Cardiff, United Kingdom.
  • Loo S; Southend Hospital, Southend, United Kingdom.
  • Marshall S; Department of Haematology, Leeds Teaching Hospitals Trust, Leeds, United Kingdom.
  • Mehta P; Department of Haematology, King's College Hospital, London, United Kingdom.
  • Murthy V; Worthing Hospital, Worthing, United Kingdom.
  • Nagumantry S; Peter MacCallum Cancer Centre, Royal Melbourne Hospital and Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.
  • Pillai S; City Hospitals Sunderland NHS Trust, Sunderland, United Kingdom.
  • Potter N; Haematology Department, University Hospital Bristol, Bristol, United Kingdom.
  • Sellar R; Centre for Clinical Haematology, University Hospitals Birmingham, Birmingham, United Kingdom.
  • Taylor T; Peterborough City Hospital, Peterborough, United Kingdom.
  • Zhao R; Royal Stoke University Hospital, University Hospital of North Midlands NHS Trust, Stoke-on-Trent, United Kingdom.
  • Russell NH; Department of Medical and Molecular Genetics, King's College London, London, United Kingdom.
  • Wei AH; Department of Haematology, University College London Hospital NHS Foundation Trust, London, United Kingdom.
  • Dillon R; Nottingham University Hospital, Nottingham, United Kingdom.
Blood ; 143(4): 336-341, 2024 Jan 25.
Article en En | MEDLINE | ID: mdl-37647641
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Sulfonamidas / Leucemia Mieloide Aguda / Compuestos Bicíclicos Heterocíclicos con Puentes / Nucleofosmina Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Año: 2024 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Sulfonamidas / Leucemia Mieloide Aguda / Compuestos Bicíclicos Heterocíclicos con Puentes / Nucleofosmina Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Año: 2024 Tipo del documento: Article